[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [@BluntForceOpt](/creator/twitter/BluntForceOpt) "$SRPT As expected co just dropped the official update after all the recent chatter. Strategic restructuring + ELEVIDYS label update now confirmed. XX% workforce reduction (500 employees) $400M in projected annual cost savings Pipeline shift to high-impact siRNA assets ELEVIDYS will carry a black box warning (resolving FDA concerns for ambulant patients) Plan submitted to resume dosing for non-ambulant patients (new protocol under review) Q2 prelim revenue: $513M ($282M from Elevidys) Co says move ensures long-term viability and sharpens focus on siRNA pipeline (FSHD DM1 IPF Huntington's etc.)"  [@BluntForceOpt](/creator/x/BluntForceOpt) on [X](/post/tweet/1945591718491165103) 2025-07-16 21:09:47 UTC XXX followers, 6129 engagements "$PSIX $WLDN $STRL $PWR $PRIM These names have been absolute beasts lately. Different sectors same story: real earnings growth strong contract pipelines and macro tailwinds (AI grid upgrades energy infrastructure and federal funding). PSIX Manufacturer of natural gas propane and gasoline-powered engines and power systems. Key markets include standby power for data centers industrial use and specialty vehicles. Quiet AI beneficiary via backup power demand. WLDN Energy and engineering consulting firm specializing in energy efficiency utility program implementation and municipal infrastructure"  [@BluntForceOpt](/creator/x/BluntForceOpt) on [X](/post/tweet/1941214206130520355) 2025-07-04 19:15:07 UTC XXX followers, XXX engagements "$CNC broke its multi-year trendline months ago and the recent flush drove it straight into key support from the 20152017 range ($27). Big structural break but also a spot where longer-term buyers may start stepping in. As noted earlier I began building a defined-risk long via 2026 LEAPS (Jun $55s Sep $50s). a slow-burn recovery setup targeting stabilization and a re-rating back toward the $5055 range over time. Once the dust settles and we get clearer signs of fundamental stabilization Ill likely begin layering in short puts at levels Im comfortable owning. If assigned great. I lower my"  [@BluntForceOpt](/creator/x/BluntForceOpt) on [X](/post/tweet/1947083753869939154) 2025-07-20 23:58:36 UTC XXX followers, 2344 engagements "$NFE Breaking down the live short data on NFE. short interest remains extremely elevated but today's tape shows signs of some short-term unwinding: Estimated Short Interest: 57.6M shares Short % of Free Float: XXXXX% Borrowed Today: 3.98M vs. Returned: 5.11M Net -1.14M IBKR Short Availability: 2.8M shares. up sharply from 1M yesterday Cost to Borrow (CTB): Latest: XXXX% Average: XXXX% Max: XXXXX% The setup is still crowded but borrow pressure is easing availability is increasing and some shorts are clearly reducing exposure into recent strength"  [@BluntForceOpt](/creator/x/BluntForceOpt) on [X](/post/tweet/1946316515290280232) 2025-07-18 21:09:52 UTC XXX followers, XXX engagements "$ALMS Anyone looking at the unusually large put position in Alumis specifically the 30000+ open Oct XX $XXXX puts heres how Im interpreting it: Yes its a big number (3M shares notional) and yes the options chain is generally illiquid. But rather than a directional bearish bet or a hedge on dilution (which seems unlikely given the $700M in cash) this setup IMO looks more like a range-bound premium strategy. Consider this: There was notable call OI in the July $X and $XXXX strikes -- now expired -- which likely reflects short call selling into strength On the flip side those Oct $XXXX puts may"  [@BluntForceOpt](/creator/x/BluntForceOpt) on [X](/post/tweet/1946662988234305704) 2025-07-19 20:06:38 UTC XXX followers, XXX engagements "Ive spent a lot of time on $SLDB and traded it with conviction but as previously mentioned Ive also stepped aside recently out of respect for the shifting risk profile -- not emotion. The reported third patient death in $SRPT in my view increases the likelihood that the FDA adopts a significantly more cautious and stringent posture particularly around accelerated approvals in gene therapy. The recent CRL for $CAPR is likely an early reflection of that shift in sentiment -- especially under the current regulatory regime. To be clear: that doesnt mean Solids platform isnt promising (Ive"  [@BluntForceOpt](/creator/x/BluntForceOpt) on [X](/post/tweet/1946173211240226842) 2025-07-18 11:40:26 UTC XXX followers, XXX engagements "$CLSD DT dilution metrics: Offering Ability = High Overhead Supply = High Cash Need = High Mkt Cap & EV: 22.9M / 17.2M Float & OS: 66.29M / 77.71M Est. Net Cash/Sh: XXXX Inst Own: XXXX% SI: XXX% The company hasapprox. XXX months of cash left based on Q cash burn of -$5.83M and estimated current cash of $6.4M. Please do your own DD"  [@BluntForceOpt](/creator/x/BluntForceOpt) on [X](/post/tweet/1947368030700474876) 2025-07-21 18:48:13 UTC XXX followers, XXX engagements "ICYMI: $KYTX has named Marc Grasso as its new Chief Financial Officer. Grasso previously served as CFO at $ALEC and brings experience from multiple clinical-stage biotech co's. Former CFO Ryan Jones will stay on in a strategic advisory role to help with the transition. CFO transitions are always notable IMO especially at the clinical stage. Worth keeping an eye on as Kyverna navigates its next phase of development"  [@BluntForceOpt](/creator/x/BluntForceOpt) on [X](/post/tweet/1939707217583960503) 2025-06-30 15:26:53 UTC XXX followers, XXX engagements "$ALMS filed a $400M mixed shelf today. No offering was priced but this filing gives them the flexibility to raise capital at any time. While the company is well-capitalized today with $730M in pro forma cash this shelf signals that management wants optionality going forward. It doesnt mean dilution is imminent but the door is now open. Worth keeping on the radar. Happy 4th. Have a great weekend ya'll"  [@BluntForceOpt](/creator/x/BluntForceOpt) on [X](/post/tweet/1940878405513404697) 2025-07-03 21:00:46 UTC XXX followers, XXX engagements "$CAT You wouldnt know it by the headlines -- not getting much attention -- but CAT has crushed X of the Mag X over the past X years. up +259.68% with a XXXXX% CAGR (give or take depending on source). Its outperformed $META $MSFT $GOOGL $AAPL and $AMZN. While everyones been glued to tech Caterpillars quietly led the charge. Giddy up 📈"  [@BluntForceOpt](/creator/x/BluntForceOpt) on [X](/post/tweet/1944472386801401914) 2025-07-13 19:01:58 UTC XXX followers, XXX engagements "$CAPR GM y'all. Heres a quick breakdown of this mornings PR regarding the FDAs Complete Response Letter: FDA says the submission lacks "substantial evidence of effectiveness." Data from HOPE-2 the open-label extension and natural history comparisons werent sufficient. Also cited unresolved CMC (manufacturing) items. Capricor says most of those were already submitted but werent reviewed due to timing. No safety concerns raised. No issues with trial conduct or data integrity. Capricor plans to resubmit its BLA in Q3 2025 incorporating data from HOPE-3 -- a randomized placebo-controlled Phase 3"  [@BluntForceOpt](/creator/x/BluntForceOpt) on [X](/post/tweet/1943628503691542860) 2025-07-11 11:08:40 UTC XXX followers, 3592 engagements "Conviction isnt about comfort. Its about catching what others only realize in hindsight. (12-Month Perf) $PLTR +421% $TSLA +39% $QQQ +18% $GOOGL +8% $AAPL X% Palantir didnt follow the market -- it led it. 🚀"  [@BluntForceOpt](/creator/x/BluntForceOpt) on [X](/post/tweet/1947793999336771726) 2025-07-22 23:00:52 UTC XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@BluntForceOpt
"$SRPT As expected co just dropped the official update after all the recent chatter. Strategic restructuring + ELEVIDYS label update now confirmed. XX% workforce reduction (500 employees) $400M in projected annual cost savings Pipeline shift to high-impact siRNA assets ELEVIDYS will carry a black box warning (resolving FDA concerns for ambulant patients) Plan submitted to resume dosing for non-ambulant patients (new protocol under review) Q2 prelim revenue: $513M ($282M from Elevidys) Co says move ensures long-term viability and sharpens focus on siRNA pipeline (FSHD DM1 IPF Huntington's etc.)"
@BluntForceOpt on X 2025-07-16 21:09:47 UTC XXX followers, 6129 engagements
"$PSIX $WLDN $STRL $PWR $PRIM These names have been absolute beasts lately. Different sectors same story: real earnings growth strong contract pipelines and macro tailwinds (AI grid upgrades energy infrastructure and federal funding). PSIX Manufacturer of natural gas propane and gasoline-powered engines and power systems. Key markets include standby power for data centers industrial use and specialty vehicles. Quiet AI beneficiary via backup power demand. WLDN Energy and engineering consulting firm specializing in energy efficiency utility program implementation and municipal infrastructure" @BluntForceOpt on X 2025-07-04 19:15:07 UTC XXX followers, XXX engagements
"$CNC broke its multi-year trendline months ago and the recent flush drove it straight into key support from the 20152017 range ($27). Big structural break but also a spot where longer-term buyers may start stepping in. As noted earlier I began building a defined-risk long via 2026 LEAPS (Jun $55s Sep $50s). a slow-burn recovery setup targeting stabilization and a re-rating back toward the $5055 range over time. Once the dust settles and we get clearer signs of fundamental stabilization Ill likely begin layering in short puts at levels Im comfortable owning. If assigned great. I lower my" @BluntForceOpt on X 2025-07-20 23:58:36 UTC XXX followers, 2344 engagements
"$NFE Breaking down the live short data on NFE. short interest remains extremely elevated but today's tape shows signs of some short-term unwinding: Estimated Short Interest: 57.6M shares Short % of Free Float: XXXXX% Borrowed Today: 3.98M vs. Returned: 5.11M Net -1.14M IBKR Short Availability: 2.8M shares. up sharply from 1M yesterday Cost to Borrow (CTB): Latest: XXXX% Average: XXXX% Max: XXXXX% The setup is still crowded but borrow pressure is easing availability is increasing and some shorts are clearly reducing exposure into recent strength" @BluntForceOpt on X 2025-07-18 21:09:52 UTC XXX followers, XXX engagements
"$ALMS Anyone looking at the unusually large put position in Alumis specifically the 30000+ open Oct XX $XXXX puts heres how Im interpreting it: Yes its a big number (3M shares notional) and yes the options chain is generally illiquid. But rather than a directional bearish bet or a hedge on dilution (which seems unlikely given the $700M in cash) this setup IMO looks more like a range-bound premium strategy. Consider this: There was notable call OI in the July $X and $XXXX strikes -- now expired -- which likely reflects short call selling into strength On the flip side those Oct $XXXX puts may" @BluntForceOpt on X 2025-07-19 20:06:38 UTC XXX followers, XXX engagements
"Ive spent a lot of time on $SLDB and traded it with conviction but as previously mentioned Ive also stepped aside recently out of respect for the shifting risk profile -- not emotion. The reported third patient death in $SRPT in my view increases the likelihood that the FDA adopts a significantly more cautious and stringent posture particularly around accelerated approvals in gene therapy. The recent CRL for $CAPR is likely an early reflection of that shift in sentiment -- especially under the current regulatory regime. To be clear: that doesnt mean Solids platform isnt promising (Ive" @BluntForceOpt on X 2025-07-18 11:40:26 UTC XXX followers, XXX engagements
"$CLSD DT dilution metrics: Offering Ability = High Overhead Supply = High Cash Need = High Mkt Cap & EV: 22.9M / 17.2M Float & OS: 66.29M / 77.71M Est. Net Cash/Sh: XXXX Inst Own: XXXX% SI: XXX% The company hasapprox. XXX months of cash left based on Q cash burn of -$5.83M and estimated current cash of $6.4M. Please do your own DD" @BluntForceOpt on X 2025-07-21 18:48:13 UTC XXX followers, XXX engagements
"ICYMI: $KYTX has named Marc Grasso as its new Chief Financial Officer. Grasso previously served as CFO at $ALEC and brings experience from multiple clinical-stage biotech co's. Former CFO Ryan Jones will stay on in a strategic advisory role to help with the transition. CFO transitions are always notable IMO especially at the clinical stage. Worth keeping an eye on as Kyverna navigates its next phase of development" @BluntForceOpt on X 2025-06-30 15:26:53 UTC XXX followers, XXX engagements
"$ALMS filed a $400M mixed shelf today. No offering was priced but this filing gives them the flexibility to raise capital at any time. While the company is well-capitalized today with $730M in pro forma cash this shelf signals that management wants optionality going forward. It doesnt mean dilution is imminent but the door is now open. Worth keeping on the radar. Happy 4th. Have a great weekend ya'll" @BluntForceOpt on X 2025-07-03 21:00:46 UTC XXX followers, XXX engagements
"$CAT You wouldnt know it by the headlines -- not getting much attention -- but CAT has crushed X of the Mag X over the past X years. up +259.68% with a XXXXX% CAGR (give or take depending on source). Its outperformed $META $MSFT $GOOGL $AAPL and $AMZN. While everyones been glued to tech Caterpillars quietly led the charge. Giddy up 📈" @BluntForceOpt on X 2025-07-13 19:01:58 UTC XXX followers, XXX engagements
"$CAPR GM y'all. Heres a quick breakdown of this mornings PR regarding the FDAs Complete Response Letter: FDA says the submission lacks "substantial evidence of effectiveness." Data from HOPE-2 the open-label extension and natural history comparisons werent sufficient. Also cited unresolved CMC (manufacturing) items. Capricor says most of those were already submitted but werent reviewed due to timing. No safety concerns raised. No issues with trial conduct or data integrity. Capricor plans to resubmit its BLA in Q3 2025 incorporating data from HOPE-3 -- a randomized placebo-controlled Phase 3" @BluntForceOpt on X 2025-07-11 11:08:40 UTC XXX followers, 3592 engagements
"Conviction isnt about comfort. Its about catching what others only realize in hindsight. (12-Month Perf) $PLTR +421% $TSLA +39% $QQQ +18% $GOOGL +8% $AAPL X% Palantir didnt follow the market -- it led it. 🚀" @BluntForceOpt on X 2025-07-22 23:00:52 UTC XXX followers, XXX engagements